Clinical Trials
1,190 trialsPROMPT
University College, London
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
NRG Oncology
DIALOGUE
University of Basel
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
FHAMe
University of Toronto
KEYLYNK-001
Merck Sharp & Dohme LLC
LEAP-005
Merck Sharp & Dohme LLC
ALISON
University Medical Center Groningen
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis
Oncoinvent Solutions AS
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
National Institutes of Health Clinical Center (CC)
CURSOC
Institut Claudius Regaud
LETSGO
Sorlandet Hospital HF
SurgiPerito Trial: High-Purity Type-I Collagen for Peritoneal Reconstruction After Cytoreductive Surgery
Adichunchanagiri Institute of Medical Sciences, B G Nagara
GYNCOG
Northwestern University
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
ROBO-GYN
Centre Oscar Lambret
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Sun Yat-sen University
BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
Dana-Farber Cancer Institute
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Sun Yat-sen University
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
MiGHT
University of Michigan Rogel Cancer Center
CATALYST
Rutgers, The State University of New Jersey
A Study of Serum Folate Levels in Patients Treated With Olaparib
Rush University Medical Center
Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer
Zhejiang Cancer Hospital
ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer
Institute of Oncology Ljubljana
CHRONO
ARCAGY/ GINECO GROUP
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
University of Alabama at Birmingham
Acupressure for Fatigue in Ovarian Cancer Survivors
University of Michigan Rogel Cancer Center
Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
Cedars-Sinai Medical Center
PREPARE
Institut Bergonié
RAF/MEK
Royal Marsden NHS Foundation Trust
QOS
University Hospital, Ghent
SABRINA
Impact Therapeutics, Inc.
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Cue Biopharma
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Lumicell, Inc.
Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
Abramson Cancer Center at Penn Medicine
PICCOLO
AbbVie
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Risen (Suzhou) Pharma Tech Co., Ltd.
METERMUS-IMC
University Hospital, Tours
EWOC-1
Hospices Civils de Lyon
ICONIC
Hospices Civils de Lyon
ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study
Memorial Sloan Kettering Cancer Center
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited